Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.